



Same Heart and Different Sleep? A Brief Review of the Association between Sleep Apnea Syndrome and Heart Failure Based on Two Clinical Cases

**Nicola Vitulano^{1*}, Francesco Perna¹, Graziano Riccioni²,
Maria Teresa Cardillo¹, Valentina Coluccia¹, Ada Francesca Giglio¹,
Massimo Gustapane¹ and Fulvio Bellocchi¹**

¹*Department of Cardiovascular Sciences, Catholic University of the Sacred Heart, Largo
A. Gemelli 1, 00168, Rome, Italy.*

²*Cardiology Unit, San Camillo De Lellis Hospital, via Isonzo, 71043, Manfredonia, Italy.*

Authors' contributions

This work was carried out in collaboration between all authors. Author NV designed the review and wrote the first draft of the manuscript. Author FP revised the entire manuscript and set its final version. Authors GR and MTC managed the literature searches. Authors VC, AFG, MG clinically managed the patients and provided the material for the clinical cases description. Author FB supervised the entire work as well as the clinical management of the patients. All authors read and approved the final manuscript.

Review Article

Received 1st May 2013
Accepted 8th July 2013
Published 14th September 2013

ABSTRACT

The research in the field of sleep medicine has increased during the whole twentieth century, principally for the involvement of sleep-related disordered breathing (SDB) in cardiovascular disease. If sleep encompasses about a third of one's life, the reasons are mostly linked to its effects on the cardiovascular and respiratory systems. Sleep is a physiological phenomenon characterized by changes in the human body leading to a state of quiescence of the cardiovascular, respiratory and metabolic systems [1]. The importance of these events becomes more evident if we

*Corresponding author: Email: nicola.vitulano@gmail.com;

consider what happens in their absence, that is, during SDB syndromes. These syndromes include habitual snoring, sleep apnea, Cheyne-Stokes breathing syndrome and sleep hypoventilation syndrome [2]. Sleep apnea syndromes are characterized by several apneic events during the night, which consist in absence of the airflow or its reduction by more than 90% lasting more than 10 seconds, with consequent oxyhemoglobin desaturation and arousal [2]. These events provoke microawakening and sleep fragmentation that represent, along with hypoxemia, important harmful triggers on the cardiovascular system. In fact, SDB presents as a highly prevalent comorbidity in patients with heart failure (HF); both diseases are related to each other in a bidirectional way through multiple mechanisms: apneic events raise cardiac afterload, and at the same time impaired cardiac function itself may contribute to the development of sleep apnea. HF is a clinical syndrome characterized by signs or symptoms due to the inability of the heart to provide a normal tissue perfusion: the failing cardiac pump is not able to maintain an adequate output for this task. Typical features of HF are represented by shortness of breath, resting or exertion dyspnea, fatigue, fluid retention leading to pulmonary congestion or ankle swelling, and objective evidence of a structurally or functionally abnormal heart at rest [1,3].

Keywords: Sleep apnea syndrome; obstructive sleep apnea; central sleep apnea; heart failure; continuous positive airway pressure.

1. INTRODUCTION

In this report we describe two cases of 38 years old men sharing a similar medical history characterized by recent onset asthenia and mild effort dyspnea with a subsequent diagnosis of non-ischemic dilated cardiomyopathy. Based on the high prevalence of SDB in patients with cardiovascular disease and the well established relationship between SDB and HF in terms of risk factors and comorbidities, we decided to perform a cardio-respiratory sleep study in both patients. This examination established a diagnosis of sleep-related disordered breathing with prevalent obstructive sleep apnea in only one of these patients, thus giving rise to a brief discussion about the complex pathophysiological relationships between HF and SDB.

1.1 Clinical Case 1

A 38-years-old Caucasian man with no previous cardiovascular events and no risk factors presented to the Emergency Department of our hospital for new onset mild effort dyspnea. Physical examination revealed protodiastolic gallop rhythm and pulmonary basal crackles. A twelve lead ECG was recorded, showing sinus tachycardia (HR: 100 bpm), possible left atrial enlargement, left anterior fascicular block and some supraventricular ectopic beats (Fig. 1.A). The chest X-rays showed widened heart silhouette and Kerley's B lines. An echocardiogram revealed significant enlargement and severe dysfunction of the left ventricle (end diastolic diameter: 70 mm; LVEF < 20%), moderate mitral valve regurgitation due to annulus dilation, significant left atrial enlargement (258 ml). The patient was admitted to the Cardiology Unit and underwent blood sample ruling out the presence of acute viral infections. In particular, IgMs and IgAs for common cardiotropic and respiratory viruses were negative, including Echovirus, Coxsackievirus, Adenovirus, Parvovirus B19, Herpes Simplex Virus, Epstein-Barr Virus, Cytomegalovirus, Orthomyxovirus and Paramyxoviruses, as well as for

Chlamydia and Rickettsia serum tests. The coronary angiography showed normal coronary arteries. A cardiac magnetic resonance evidenced severe biventricular dysfunction and enlargement and ruled out the presence of areas of edema and delayed enhancement (Fig. 1.B). Beta-blockers, ARBs (up-titrated to the highest tolerated doses) and diuretics were administered with clinical benefit and a primary prevention single-chamber implantable cardioverter-defibrillator was implanted three months later because of persistent low ejection fraction despite optimal medical therapy.

The patient had a body mass index (BMI) of 27.4 Kg/m², a waist circumference of 104 cm with a sagittal-abdominal diameter of 28 cm, and a neck circumference of 44 cm. The patient showed normal facial profile and pharyngeal structure (modified Mallampati class I). He had no history of smoking or alcohol abuse. No history of either upper respiratory tract infection or sleep-disordered breathing was present. The patient's Epworth Sleepiness Scale was 9.

1.2 Clinical Case 2

A 38-years-old Caucasian man with recent onset hypertension came to our Emergency Department for paroxysmal nocturnal dyspnea and chest oppression. The chest-X rays showed interstitial pulmonary edema and cardiac dilation, twelve lead ECG showed new onset left bundle branch block and atrial flutter with 2:1 atrioventricular ratio (Fig. 2.A) (the left bundle branch regressed after treatment of supraventricular tachycardia and rate control). The patient was then recovered into the Cardiac Intensive Care Unit. The echocardiogram showed severe left ventricular dysfunction (LVEF < 20%), global left ventricular hypokinesis, bi-atrial enlargement and slightly enlarged right ventricle; severe pulmonary hypertension was also found (PAPS 65 mmHg). Blood samples ruled out the presence of acute viral infections. In particular, IgMs and IgAs for common cardiotropic and respiratory viruses were negative, including Echovirus, Coxsackievirus, Adenovirus, Parvovirus B19, Herpes Simplex Virus, Epstein-Barr Virus, Cytomegalovirus, Orthomyxovirus and Paramyxoviruses, as well as for Chlamydia and Rickettsia serum tests. The coronary angiography found no signs of atherosclerosis. During the hospitalization beta-blockers, ACE-inhibitors (up-titrated to the highest tolerated doses) and diuretics were administered with improvement of the patient's clinical conditions. A cardiac magnetic resonance evidenced severe reduction of the systolic left ventricular function, normal right ventricular function and few areas of intramyocardial interventricular septal delayed enhancement which were, however, inconsistent with prior myocarditis (Fig. 2.B). A single-chamber implantable cardioverter-defibrillator was then implanted in primary prevention three months later because of persistent low ejection fraction despite optimal medical therapy.

The patient had BMI of 28.7 Kg/m², a waist circumference of 100 cm with sagittal-abdominal diameter of 27 cm, and a neck circumference of 41 cm. The patient showed normal facial profile and pharyngeal structure (modified Mallampati class I). He had no history of smoking or alcohol abuse. No history of either upper respiratory tract infection or sleep-disordered breathing was present. The patient's Epworth Sleepiness Scale was 7.

1.3 Cardiorespiratory Sleep Study

Since both patients complained of nocturnal snoring, dryness of mouth at the awakening and daytime sleepiness, we decided to perform a cardiorespiratory sleep study to detect the presence of SDB.

For patient 1, the cardiorespiratory sleep study embraced a 6-hour period. A total of 30 obstructive sleep apneas (OSA), 14.5 central sleep apneas (CSA), 7.3 mixed sleep apneas and 4.5 hypopneas per hour were detected, with an Apnea-Hypopnea Index (AHI) of 56.3/hour. Five-hundred and fifty snoring episodes were recorded throughout the sleep study. Mean and minimum SpO₂ were 92% and 74%, respectively. The Oxygen desaturation Index (ODI) was 28.2/hour. Severe sleep apnea syndrome was eventually diagnosed.

For patient 2, the cardiorespiratory sleep study embraced a 7-hour period. A total of 0.9 OSA, 0.3 CSA, 0.3 mixed sleep apneas and 2 hypopneas per hour were detected, with an Apnea-Hypopnea Index (AHI) of 3.5/hour. One-hundred and ninety-two snoring episodes were recorded throughout the sleep study. Mean and minimum SpO₂ were 94% and 67%, respectively. The Oxygen desaturation Index (ODI) was 2.8/hour; thus not matching the diagnostic criteria for sleep apnea syndrome (Fig. 1.C-D, 2.C-D).




Fig. 1. A twelve lead ECG showed sinus tachycardia (HR: 100 bpm), left anterior fascicular block and some supraventricular ectopic beats (Fig. 1.A). A cardiac magnetic resonance evidenced severe biventricular dysfunction and enlargement and ruled out the presence of areas of edema and delayed enhancement (Fig. 1.B). A cardiorespiratory sleep study to detect the presence of SDB revealed obstructive sleep apnea (OSA) highlighted in dark violet and central sleep apnea (CSA) in pink. In fact in the apneic events there is absence of the airflow and the criterion differentiating between obstructive and central is the concomitant presence or absence efforts to breathe, respectively, pointed out through the registration of thorax and abdominal movement (Fig. 1.C-D)




Fig. 2. A twelve-lead ECG showed new onset left bundle branch block and atrial flutter with 2:1 atrioventricular ratio (Fig. 2. A). A cardiac magnetic resonance evidenced severe reduction of the systolic left ventricular function, normal right ventricular function (Fig. 2. B). A cardiorespiratory sleep study does not show apneic events in significant number, but only short phases of hypopnea and brief obstructive sleep events during nightly breathing (2. C-D)

2. SLEEP APNEA SYNDROME AND HEART FAILURE

Recent data showed a raising prevalence of SDB in the general population, with moderate to severe SDB affecting 10% of 30–49-year-old men, 17% of 50–70-year-old men, 3% of 30–49-year-old women and 9% of 50–70 year-old women [4]. The prevalence of SDB might be even higher among HF patients. Those patients are reported to have a prevalence of OSA ranging from 12 to 53% in polysomnography studies [5,6,7]. In addition, more than 55% of patients with OSA have diastolic dysfunction [8]. Numerous studies investigated the prevalence of SDB in the context of HF, reporting inhomogeneous results because of the use of different cutoffs of AHI, variable heart failure severity, dissimilar comorbidities and risk factors between studies.

OSA was found in approximately 11% of 81 ambulatory male patients with systolic HF and a mean EF of 25% [9]. Few years later, the same group prospectively analyzed 100 ambulatory male patients with HF and mean EF of 24% and found a 12% prevalence of OSA. [10] In a similar way Vazir et al [7] found the prevalence of OSA to be 15% among male patients with mild symptomatic HF, and in another prospective study including female patients Wang et al. [11] reported a 26% prevalence among 218 heart failure

patients with a LVEF lower than 45%. A retrospective study conducted by Sin et al on a larger population of 450 patients with systolic HF showed that 37% of the study population suffered from OSA [12]. In a similar fashion, Ferrier et al found the prevalence of OSA to be 53% in 53 stable HF outpatients [6]. However, the two latter studies used a AHI cutoff of 10/h and included patients with higher EF (anyway remaining below 45%). Further data supported a high OSA prevalence in HF, in fact Oldenburg et al. [13] studying 700 HF patients with New York Heart Association (NYHA) Class \geq II, found that 36% were affected by OSA based on a AHI cutoff of \geq 5/h.

The same studies also described the prevalence of central sleep apnea (CSA) in patients with chronic HF. Javaheri et al found CSA prevalence of 40% and 37% in subsequent studies enrolling ambulatory male patients with HF [9,10]. The studies by Vazir and Wang showed the prevalence of CSA in HF patients to be 38% and 21%, respectively, with the second study also including female patients [7,11]. In their retrospective study on 450 consecutive patients with systolic HF, Sin et al. found a 33% prevalence of CSA [12], and in a similar way Ferrier et al found a CSA prevalence of 15% [6]. In another study using the minimum AHI cutoff (5/h), CSA prevalence was as high as 40 % (13). Table 1 provides an overview of the prevalence of OSA and CSA in various studies which enrolled patients with HF.

Those findings all together point out the importance of SDB in HF patients, despite a dissimilar prevalence in different studies. The basis of such discrepancy might be represented by the use of different cutoff values, dissimilar patient populations in terms of ethnicity and gender prevalence, concomitant presence of both types of apnea and their different classification according to the relative percentage of one of the two types of SDB. Besides, since CSA seems to be associated with more advanced HF, the presence of patients with more severe HF might play an important role as a selection bias in some studies. Recent investigations also showed a high prevalence of SDB, predominantly OSA, among patients with stable HF with NYHA class II-IV and preserved ejection fraction [14].

3. PATHOPHYSIOLOGY OF SLEEP APNEA IN THE PRESENCE OF HEART FAILURE

In patients with HF the heart is unable to provide an adequate cardiac output, thus causing increased fluid retention. A higher prevalence of both obstructive and central sleep apnea, which can coexist in the same subject, has been shown in this population. A recent study hypothesized a possible common pathophysiological pathway underlying both types of apnea in patients with systolic HF [15]. Researchers try to elucidate the complex mechanisms linking the two types of apneic events and HF through three pathways. The first one suggests an anatomical and mechanical point of view regarding the swelling of the upper parts of the neck due to fluid clutter that causes obstruction; the second hypothesis about CSA still considers nightly fluid accumulation as a starting point, but in this case a prevalent pulmonary component plays a pivotal role by influencing the chemoreceptors rather the mechanical stress only; finally autonomic deregulation, imbalance of O₂ and PCO₂ levels and electrolyte disorders which are related to HF contribute to sleep breathing disorders. In HF patients, a nocturnal rostral fluid shift from the legs has been documented by a reduction in the leg fluid volume and calf circumference. At the same time, an increased neck circumference has been observed, which can be related to soft tissues congestion, loss

of dilator pharyngeal muscles tone resulting in a pharyngeal obstruction with a consequent and progressive reduction of airflow during nightly breath, thus explaining the occurrence of obstructive apnea events. On the other hand, in patients experiencing central apnea events there is a more pronounced reduction of leg fluid volume which is only partially explained by the increase of neck circumference, suggesting that part of these fluids, concentrating at thoracic level, may be responsible for augmented pulmonary congestion and filling pressures in these patients [15]. Pulmonary congestion is directly related to the pathogenesis of central apnea events through hindered pulmonary gas exchange, characterized by a progressive reduction of PaO₂ below the threshold of the physiological nocturnal reduction of 4-10 mmHg and an increase of PaCO₂ above the 3-7 mmHg usually observed in a normal sleep. These alterations linked to mechanical strain provoke a stimulation of pulmonary J receptors [16]. The combination of the above mentioned phenomena triggers hyperventilation, subsequently leading to PaCO₂ reduction below the so-called apnea threshold, thus suppressing stimulation of the respiratory muscles and causing phases of central apnea. The imbalance of PO₂ and PCO₂ concentration, caused by both OSA and CSA, stimulates the central nervous system, thus increasing the ventilation rate, provoking arousals with sleep fragmentation and respiratory fatigue with a consequent sleep deprivation; this causes not only an abnormal nightly activation of sympathetic nervous system but also an increased sympathetic tone during the day which is detrimental to a failing heart (Fig. 3). The interaction between CSA and HF is therefore complex; fluid retention seems to be a key mechanism linking these two conditions, as also suggested by the recently proven association between excessive sodium intake (with subsequent intra- and extra-vascular plasma volume expansion) and sleep apnea in patients with HF [17-20].

4. TREATMENT OF SLEEP APNEA SYNDROME IN THE SETTING OF HEART FAILURE

Despite continuous treatment advancements, patients with HF have a poor prognosis. Worsening clinical conditions often require progressive therapeutic adjustments. The therapeutic options for HF encompass both pharmacological and electrical treatment: beta-blockers, renin-angiotenin-aldosterone system antagonists and diuretics, cardiac resynchronization therapy and implantable cardioverter-defibrillators. At the same time it is important to treat all the other conditions that might contribute to worsen HF such as sleep apnea syndrome. The primary choice in the treatment of sleep apnea syndrome is characterized by the nightly use of continuous positive airpressure of ventilatory support, such as Automatic Positive Airway Pressure (APAP), Automatic Continuous Airway Pressure (CPAP), bilevel Positive Airway Pressure (bi-PAP), or adaptive servo-ventilation, depending on the type and the amount of the apneic events and on the underlying cardiac and respiratory conditions. Several studies have shown the advantages of this therapeutic option for patients with sleep apnea also in terms of blood pressure [21,22] and improved insulin sensitivity [23]. The left ventricular ejection fraction is improved in HF patients when OSA is treated with CPAP [24,25]. Although the CANPAP trial failed to show any impact of CPAP on heart transplant-free survival, a post-hoc analysis demonstrated that if CSA is suppressed soon through the use of CPAP, this results in an improvement of both left ventricular ejection fraction and heart transplant-free survival. [26] In patients with chronic HF, OSA and CSA often co-exist; adaptive servoventilation effectively reduced all forms of SDB and improved left ventricular ejection fraction at six-months follow-up in a small study [27].

Table 1. The main clinical studies investigating the prevalence of sleep apnea among heart failure patients

Study	Patients(n)	Age (years, mean \pm SD)	Gender M/F (n)	Mean LVEF (%)	NYHA functional class	AHI Cutoff (events/hour)	OSA + CSA prevalence (%)	OSA prevalence (%)	CSA Prevalence (%)
<i>Javaheri, 1998</i>	81	64 \pm 10,5	81/0	25	I-III	\geq 15	51	11	40
<i>Sin, 1999</i>	450	60 \pm 13,6	382/68	27,3	II-IV	\geq 10	70	37	33
<i>Ferrier, 2005</i>	53	60,1 \pm 9,8	41/12	34	I-II	\geq 10	68	53	15
<i>Javaheri, 2006</i>	100	64 \pm 10	100/0	24	I-III	\geq 15	49	12	37
<i>Vazir, 2007</i>	55	61 \pm 12	55/0	30,6	II	$>$ 15	53	15	38
<i>Wang, 2007</i>	218	55 \pm 11,7	120/44	25	II-IV	\geq 15	47	26	21
<i>Oldenburg, 2007</i>	700	64,5 \pm 10,4	561/139	28,3	II-IV	$>$ 5	76	36	40
<i>Herrscher, 2011</i>	71	61.4 \pm 9.5	60/11	29,6	II-IV	\geq 5	81	49	32




Fig. 3. Patients with HF show increased fluid retention with a nocturnal rostral fluid shift from the legs and increased neck circumference and loss of dilator pharyngeal muscles tone and pharyngeal obstruction, thus explaining the occurrence of obstructive apnea events. On the other hand, in patients experiencing central apnea events part of these fluids may be responsible of augmented pulmonary congestion directly related to the pathogenesis of central apnea events through an imbalance of pulmonary gas exchange and stimulation of pulmonary J receptors. The combination of these alterations triggers hyperventilation, subsequently leading to PaCO₂ reduction below the so-called apnea threshold, thus suppressing stimulation of the respiratory muscles and causing phases of apnea. This imbalance of PO₂ and PCO₂ concentration stimulates the central nervous system, thus increasing the ventilation rate and provoking arousals with sleep fragmentation and respiratory fatigue that further worsen the underlying cardiac condition (Fig. 3)

5. LIMITATIONS

We performed the cardiorespiratory sleep studies using a portable monitor. This is the major limitation of the study, since in patients with several comorbid conditions, such as congestive heart failure patients, a complete polysomnography is recommended. However, the use of less expensive and easily available portable monitors for the detection of sleep apneas in heart failure patients has been shown to be an acceptable option by some authors [28], especially if a relatively high pre-test probability is present, as in our case patients who both complained of typical symptoms.

6. CONCLUSIONS

In spite of the currently available knowledge about SDB and heart failure, several aspects of the relationship between these two conditions remain unknown. The clinical

cases reported herein underline the complexity of such connections, that are at times not as straightforward as one might expect. Although SDB are likely to affect patients with severe HF, thus mandating further investigations such as polysomnography in this subpopulation, some of these patients might not show apneic events during the night, as observed in the second clinical case. The exact relationship between SDB and HF is still under investigation, and nowadays many questions are still unanswered. Should every patient with HF be screened for the presence of SDB? Are there any clinical or pathological features that are able to strongly suggest the presence of SDB in HF patients? Are patients with HF associated to SDB subject to a different degree of severity of nightly desaturations or apneic events than the remainder of SDB patients? Do they respond in a significantly different manner to ventilation therapy, either better or worse? As shown in our reports, every clinical case could present different characteristics. Probably, further pathophysiological pathways in addition to the ones described in this brief review act in the complex cascade of events that in the setting of HF eventually provoke apneic events thus contributing to worsen this condition. Several other topics are still under debate. For example, the contribution of the right ventricle to pulmonary congestion through fluid retention and its rostral nightly distribution is currently unclear. At the same time, a different impact on the presence of SDB might be determined by the underlying cardiomyopathy, with different etiologies leading to a different risk of developing SDB due to their diverse involvement of cardiac wall areas and autonomic system receptors. The role of the sympathetic autonomic system also remains incompletely explained as well as the role played by autonomic triggers in different cardiac diseases. Further studies are warranted to better understand the reciprocal interplay of HF and SDB and the specific role of the apnea treatment by ventilatory support in the armamentarium of HF therapies.

DISCLOSURES

The authors report no disclosures.

CONSENT

All authors declare that written informed consent was obtained from the patients for publication of this case report and accompanying images.

ETHICAL APPROVAL

Not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Naughton MT, Lorenzi-Filho G. Sleep in heart failure. *Prog Cardiovasc Dis.* 2009;51:339-49.
2. The Report of an American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. *Sleep.* 1999;22:667-689.

3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ. ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur J Heart Fail.* 2008;10:933-89.
4. Peppard PE, Young T, Barnet JH, Palta M. Increased Prevalence of Sleep-Disordered Breathing in Adults. *Am J Epidemiol.* 2013;177:1006–1014
5. Yumino D, Wang H, Floras JS, Newton GE. Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction. *J Card Fail.* 2009;15:279-85.
6. Ferrier K, Campbell A, Yee B, Richards M. Sleep-disordered breathing occurs frequently in stable outpatients with congestive heart failure. *Chest.* 2005;128:2116-22.
7. Vazir A, Hastings PC, Dayer M, McIntyre HF. A high prevalence of sleep disordered breathing in men with mild symptomatic chronic heart failure due to left ventricular systolic dysfunction. *Eur J Heart Fail.* 2007;9:243-50.
8. Chan J, Sanderson J, Chan W, Lai C. Prevalence of sleep-disordered breathing in diastolic heart failure. *Chest.* 1997;111:1488-93.
9. Javaheri S, Parker TJ, Liming JD, Corbett WS. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. *Circulation.* 1998;97:2154-9.
10. Javaheri S. Sleep disorders in systolic heart failure: a prospective study of 100 male patients. The final report. *Int J Cardiol.* 2006;106:21-8.
11. Wang H, Parker JD, Newton GE, Floras JS. Influence of obstructive sleep apnea on mortality in patients with heart failure. *J Am Coll Cardiol.* 2007;49:1625-31.
12. Sin DD, Fitzgerald F, Parker JD, Newton G. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. *Am J Respir Crit Care Med.* 1999;160:1101-6.
13. Oldenburg O, Lamp B, Faber L, Teschler H. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. *Eur J Heart Failure.* 2007;9:251-7.
14. Herrscher TE, Akre H, Overland B, Sandvik L. High prevalence of sleep apnea in heart failure outpatients: even in patients with preserved systolic function. *J Card Fail.* 2011;17:420-5.
15. Yumino D, Redolfi S, Ruttanaumpawan P, Su MC. Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. *Circulation.* 2010 Apr 13;121:1598-605.
16. Nava S, Fanfulla F. Ventilazione meccanica non invasiva. *Cap.* 23:177-190
17. Muller M. Central sleep apnoea syndrome in chronic heart failure: an underestimated and treatable comorbidity. *Neth Heart Journal.* 2010;18:260-263.
18. Crowell JW, Guyton AC, Moore JW. Basic oscillating mechanism of Cheyne-Stokes breathing. *Am J Physiol.* 1956;187:395-8.
19. Javaheri S. Central sleep apnea in congestive heart failure: prevalence, mechanisms, impact, and therapeutic options. *Semin Respir Crit Care Med.* 2005;26:44-55.
20. Kasai T, Arcand J, Allard JP, Mak S. Relationship between sodium intake and sleep apnea in patients with heart failure, *JACC.* 2011;58:1970-4.

21. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. *Am J Respir Crit Care Med.* 2001;163:344–348.
22. Wilcox I, Grunstein RR, Hedner JA, Doyle J. Effect of nasal continuous positive airway pressure during sleep on 24-hour blood pressure in obstructive sleep apnea. *Sleep.* 1993;16:539–544.
23. Harsch IA, Schahin SP, Radespiel-Troger M, Weintz O. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. *Am J Respir Crit Care Med.* 2004;169:156–162.
24. Kaneko Y, Floras JS, Usui K, Plante J. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. *N Engl J Med.* 2003;348:1233–1241.
25. Malone S, Liu PP, Holloway R, Rutherford R. Obstructive sleep apnoea in patients with dilated cardiomyopathy: effects of continuous positive airway pressure. *Lancet* 1991;338:1480–1484.
26. Arzt M, Floras JS, Logan AG, Kimoff RJ. CANPAP Investigators. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). *Circulation.* 2007;115:3173-80.
27. Hastings PC, Vazir A, Meadows GE, Dayer M. Adaptive servo-ventilation in heart failure patients with sleep apnea: a real world study. *Int J Cardiol.* 2010;139:17-24.
28. Dolliner P, Brammen L, Graf S, Huelsmann M. Portable recording for detecting sleep disorder breathing in patients under the care of a heart failure clinic. *Clin res Cardiol.* Epub ahead of print; 12 Apr 2013.

© 2014 Vitulano et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<http://www.sciencedomain.org/review-history.php?iid=215&id=12&aid=1998>